Intravenous iron

Phase 2

Intravenous iron is one of 2 therapeutic programs targeting POTS - Postural Orthostatic Tachycardia Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

POTS - Postural Orthostatic Tachycardia SyndromeActive, not recruiting

POTS - Postural Orthostatic Tachycardia SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

1 competitor in POTS - Postural Orthostatic Tachycardia Syndrome

#DrugCompanyPhaseTrials

Iron

WWatson Pharmaceuticals

Phase 2

1 2

Intravenous iron

VVanderbilt University Medical Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

POTS - Postural Orthostatic Tachycardia Syndrome

NCT07197905

Clinical

Trials by Indication[1]

POTS - Postural Orthostatic Tachycardia Syndrome1 trial

Restoring Iron Deficiency to Expand Blood Volume and Improve POTS

Active, not recruiting·VVanderbilt University Medical Center·Phase 2·NCT07197905·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intravenous iron. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Intravenous iron. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Vanderbilt University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: VVanderbilt University Medical Center

Intravenous iron

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

POTS - Postural Orthostatic Tachycardia Syndrome1 trial

References

Drug Info

Quick Facts

Related News